Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Enovis (ENOV) Preferred Shares Issued (2012)

Enovis (ENOV) reported Preferred Shares Issued of -$60000.0 for Q2 2012, down 100.02% on a QoQ basis from $333.0 million in Q1 2012.

Enovis (ENOV) has 1 years of Preferred Shares Issued data on file, last reported at -$60000.0 in Q2 2012.

  • Quarterly Preferred Shares Issued changed N/A year-over-year to -$60000.0 in Q2 2012, while the trailing twelve-month figure through Mar 2013 was -$60000.0 (changed N/A YoY) and the FY2012 annual result came in at $333.0 million, changed N/A from the prior year.
  • Preferred Shares Issued eased to -$60000.0 in Q2 2012 per ENOV's latest filing, from $333.0 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $333.0 million in Q1 2012 and bottomed at -$60000.0 in Q2 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Enovis 1.25 Bn 1.22 Bn 365.49 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 29, 2012 -60,000.00
Jun 29, 2012 -60,000.00
Mar 30, 2012 333.03 Mn
Mar 30, 2012 333.03 Mn